期刊文献+

双倍剂量科素亚治疗慢性肾炎肾性高血压的临床分析 被引量:1

Clinical Analysis of double dosage Losartan on renal hypertension patients with chronic glomerulonephritis
原文传递
导出
摘要 目的探讨双倍剂量科素亚治疗慢性肾炎肾性高血压的临床疗效和安全性。方法将50例肾性高血压患者分为科素亚单倍剂量组和科素亚双倍剂量组,分别应用科素亚50mg和100mg治疗12周,观察两组患者治疗前后血压、24小时尿蛋白定量、肝肾功能、血脂的变化和不良反应。结果两组患者的血压、24小时尿蛋白定量和尿酸水平均有显著性下降(P<0.05),而血肌酐、血钾、肝功能无显著变化(P>0.05);与单倍剂量科素亚治疗组比较,双倍剂量组患者治疗后24小时尿蛋白定量显著下降(P<0.05)。结论两组剂量科素亚治疗肾性高血压均有效,具有良好的安全性,但双倍剂量较单倍剂量科素亚对肾脏的保护作用更好。 Objective To investigate the clinical effect and safety of double dosage Losartan on renal hypertension patients with chronic glomerulonephritis. Methods 50 patients with renal hypertension were divided into signal dosage group ( Losartan 50mg qd ) and double dosage group ( Losartan 100 mg qd ) for 12 weeks, blood pressure, proteinuria in 24 hours,liver function, renal function and serum lipid were detected before and after 12 weeks. Results After treated with Losarsan, blood pressure,24h proteinuria and serum uric acid (UA) were decreased significantly (P 〈 0.05 )in two groups, but sCr, serum kalium and liver function were not changed significantly (P 〉0.05) ;comparing with the signal dosage group,24h proteinuria in double dosage group was decreased significantly (P 〈 0.05). Conclusion Treatment of renal hypertension with signal dosage and double dosage Losartan were effective and safe. Comparing to signal dosage losartan. 100mg losartan is more helpful to renal diseases.
出处 《临床内科杂志》 CAS 2006年第11期728-730,共3页 Journal of Clinical Internal Medicine
基金 上海市卫生局重点攻关课题(2003ZD001) 上海市医苑新星基金(02XX46)资助
关键词 科素亚 慢性肾小球肾炎 肾性高血压 双倍剂量 治疗 Losartan Chronic glomerulonephritis Renal hypertension Double dosage Therapy
  • 相关文献

参考文献9

  • 1Bloom BS.Continuation of initial antihypertensive medication after 1 year of therapy.Clin Ther,1998,20:671-681. 被引量:1
  • 2Corman B,Vienet R.Converting enzyme inhibition prevents postprandial hyperfilteration in rats with renal mass ablation.Am J Hypertens,1991,4:S253-S257. 被引量:1
  • 3Roberto F,Annalisa Z,Amedeo M,et al.Comparative efficacy of Losartan and Valsartan in mild-moderate hypertension:results of 24-hour ambulatory blood pressure monitoring.Current Ther Res,1999,60:195-205. 被引量:1
  • 4Eddy AA,Giachelli CM.Renal expression of gene that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria.Kidney Int,1995,47:1546-1554. 被引量:1
  • 5Anderson S,Tamow L,Rossing P,et al.Renoprotective effects of angiotensin Ⅱ receptor blockade in type Ⅰ diabetic patients with diabetic nephropathy.Kidney Int,2000,57:601-606. 被引量:1
  • 6Erlay CM,Bader B,Scheu M,et al.Renal haemodynamics in essential hypertensives treated with Losartan.Clin Nephrol,1995,43 (suppl 1):S8-S11. 被引量:1
  • 7Triggle DJ.Angiotensin Ⅱ antagonism:Losartan-sites and mechanism of action.Clin Ther,1995,17:1005-1029. 被引量:1
  • 8Remuzzi A,Perio N,Sangalli F,et al.ACEI and AGII receptor blockade improve glomerular size-selectivity in IgAN.Am J Physiol,1999,276(3pt2):F457-4666(3pt2):F457-466. 被引量:1
  • 9马骥,陈靖,林善锬,陈楠,袁伟杰,王笑云,刘必成,陈健,徐玉兰,张欣州,邓安国,舒贵阳,张金黎,刘惠.氯沙坦降低中国慢性肾脏病患者尿蛋白的临床研究[J].中华内科杂志,2004,43(12):932-933. 被引量:5

二级参考文献4

  • 1Andersen S, Rossing P, Juhl TR, et al. Optimal dose of losartan for renoprotection in diabetic nephropathy.Nephrol Dial Transplant,2002,17:1413-1418. 被引量:1
  • 2Cinotti GA, Zucchelli PC.Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies.Nephrol Dial Transplant,2001,16:961-966. 被引量:1
  • 3Remuzzi G, Bertani T.Pathophysiology of progressive nephropathies.N Engl J Med,1998,339:1448-1456. 被引量:1
  • 4Puig JG, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens, 1999,17:869-872. 被引量:1

共引文献4

同被引文献2

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部